HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
RG 12915
structure given in first source
Also Known As:
4-(N-(1-azabicyclo(2.2.2)-octan-3-yl))-2-chloro-5a,6,7,8,9,9a-hexahydrobenzofurancarboxamide; RG-12915
Networked:
3
relevant articles (
1
outcomes,
2
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
Bridged-Ring Heterocyclic Compounds
Heterocyclic Bridged Bicyclo Compounds
RG 12915: 3
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Benzofurans: 26
RG 12915: 3
Related Diseases
1.
Vomiting
08/01/1990 - "
RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.
"
11/01/1993 - "
Twenty-six patients receiving chemotherapy likely to cause vomiting received a single intravenous dose of RG 12915 at a rate of 3 ml/minute beginning 60 minutes before chemotherapy.
"
08/01/1990 - "
dose (1 mg/kg) in which RG 12915 is highly protective against cisplatin-induced emesis in the dog, RG 12915 has no significant gastroprokinetic activity in the same species.
"
08/01/1990 - "
RG 12915 [4-[N-(1-azabicyclo[2.2.2.]octan-3-(S)-yl)]2-chloro-cis 5a-(S)-9a-(S)-5a,6,7,8,9,9a-hexahydrobenzofurancarboxamide hydrochloride] is a potent and effective agent against cisplatin-induced emesis in the ferret after i.v. or p.o.
"
11/01/1993 - "
Single intravenous doses of RG 12915 prevented or lessened emesis caused by chemotherapy, including cisplatin given at doses of greater than or equal to 100 mg/m2.
"
2.
Neoplasms (Cancer)
09/01/1995 - "
RG 12915, a selective 5-HT3 antagonist developed for the treatment of emesis and nausea associated with cancer chemotherapy, was administered by gavage to four groups of pregnant rats from Gestation Day 6 to 17 at doses of 0, 1, 10, and 100 mg/kg/day, as part of a Segment II (developmental toxicity) study.
"
3.
Nausea
09/01/1995 - "
RG 12915, a selective 5-HT3 antagonist developed for the treatment of emesis and nausea associated with cancer chemotherapy, was administered by gavage to four groups of pregnant rats from Gestation Day 6 to 17 at doses of 0, 1, 10, and 100 mg/kg/day, as part of a Segment II (developmental toxicity) study.
"
Related Drugs and Biologics
1.
Cisplatin (Platino)
2.
Serotonin 5-HT3 Receptor Antagonists
3.
Antiemetics
4.
Spiperone
5.
Metoclopramide (Reglan)
6.
Apomorphine
Related Therapies and Procedures
1.
Drug Therapy (Chemotherapy)